Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Insurance
    • Bupa completes...

    Bupa completes acquisition of additional 23 per cent stake in Max JV

    Written by savita thakur thakur Published On 2016-06-14T12:16:48+05:30  |  Updated On 14 Jun 2016 12:16 PM IST

    New Delhi : Global healthcare group Bupa has completed the transaction to pick up another 23 per cent stake in its Indian joint venture Max Bupa for Rs 206.54 crore.


    Max Financial Services Ltd (formerly Max India) in November last year decided to divest 23 per cent stake in the joint venture Max Bupa Health Insurance Company (Max Bupa) to raise it to the maximum sectoral cap of 49 per cent.


    Prior to this deal Bupa held 26 per cent in the joint venture.


    "We would like to inform you that subsequent to all requisite approvals, Max India Ltd transferred 23 per cent of the total paid up share capital of Max Bupa to Bupa, Singapore, for a total consideration of Rs 206.54 crore," Max Financial Services (MFSL) said in a regulatory filing.


    Consequent to the transaction, the equity stake of Max India in Max Bupa is 51 per cent and the balance is held by Bupa, it said.


    Bupa's decision to hike its shareholding followed changes in India's foreign direct investment rules that now allow up to 49 per cent ownership of insurance companies by foreign investors.


    "Bupa has paid Rs 207 crore (approximately GBP 21.9 million) to Max India, in an all cash transaction, for the stake increase," said a company press release.


    Rahul Khosla, president, Max Group and Chairman, Max India, said, "Bupa's stake increase is a clear affirmation of the huge growth opportunity for health insurance in India. The proceedings received from the transaction will support the growth aspirations of Max India, as well as Max Bupa.


    "We have completed the transaction with our partners, Max India, to increase our shareholding in Max Bupa to 49 per cent. Bupa's commitment to the Indian health insurance market is strong, demonstrated by the speed with which we have moved to increase our shareholding," said David Fletcher, Managing Director of International Development Markets at Bupa.


    The UK-based Bupa has a presence in 190 countries. The Max Group of India is a diversified entity with presence in life insurance, health and allied businesses, and packaging sector.

    BupaDavid Fletcherhealth insuranceHealthcareMax BupaMax Financial ServicesMFSLRahul Khosla
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok